Randomized placebo-controlled double-blind cross-over study on antihypoxidotic effects of piracetam using psychophysiological measures in healthy volunteers.
The effects of two acute doses (1600 mg, 2400 mg) of 2-oxo-pyrrolidine-1-acetamide (piracetam, Normabraïn) on hypoxia resistance were screened vs placebo in a randomized, double-blind 3-way change-over design in 9 healthy male volunteers (mean age: 26.4 +/- 3.5 years; mean body weight: 74.9 +/- 8.4 kg). Psychophysiological measurements were done with the oculodynamic test (ODT) for oculomotor, performatory and additional cardiorespiratory parameters. Intradiurnal assessments were done under normoxia (prevalue) and hypoxic hypoxidosis (1 hypoxic prevalue, 3 postdose values: 1.0, 2.5 and 4.0 h) with a content of 10.5% O2 and 89.5% N2 in inspired air (hypoxic hypoxidosis)--as a model of brain dysfunctions, related with several types of senile dementia (Primary Degenerative Dementia = Alzheimer type; Multi Infarct Dementia). The results indicate that piracetam especially in its higher dose (2400 mg) displays antihypoxidotic effects already after a single administration in oculomotor, performatory and cardiorespiratory parameters.
Schaffler
K
K
Institute for Pharmacodynamic Research, Munich, Fed. Rep. of Germany.
Klausnitzer
W
W
D000328:Adult; D004311:Double-Blind Method; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D000860:Hypoxia / Q000517:prevention & control* / Q000523:psychology; D008297:Male; D010889:Piracetam / Q000627:therapeutic use*; D011597:Psychomotor Performance / Q000187:drug effects*; D011760:Pyrrolidinones / Q000627:therapeutic use*; D011897:Random Allocation; D011930:Reaction Time / Q000187:drug effects; D012119:Respiration / Q000187:drug effects; D013997:Time Factors
D011760:Pyrrolidinones; D010889:Piracetam